Dyspareunia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for dyspareunia. 5 active patents protecting 2 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

2
Approved drugs
5
Active US patents
65/100
Avg vulnerability
—
Annual revenue covered

Originators in Dyspareunia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Duchesnay 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating dyspareunia. Each bar = one year. Y-axis scaled to peak year (2 patents).

1
26
2
28
1
30
1
31

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Intrarosa
PRASTERONE
 — 3 57 — 2028-08-07
Osphena
OSPEMIFENE
 Duchesnay 2 73 — 2026-08-11

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8236861 Osphena method of use 85 2026-08-11
8957054 Intrarosa method of use 68 2030-01-08
8642079 Osphena formulation 60 2028-07-09
8629129 Intrarosa formulation 55 2028-08-07
8268806 Intrarosa formulation 48 2031-03-19

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8268806 Intrarosa formulation 48 2031-03-19
8629129 Intrarosa formulation 55 2028-08-07
8642079 Osphena formulation 60 2028-07-09
8957054 Intrarosa method of use 68 2030-01-08
8236861 Osphena method of use 85 2026-08-11

Related